https://www.mskcc.org/news-releases/results-indicate-larotrectinib-effective-first-novel-targeted-therapy-show-consistent-response-across-multiple-tumor-types-adult-and-pediatric-patients
Breakthrough findings illustrate the promise of precision oncology and signify a paradigm shift in drug development. Interim data from three trials show a 76...
first novelresultsindicatelarotrectinibeffective
https://www.stjude.org/research/progress/2018/loxo-101-larotrectinib-response-rates-for-solid-tumors-with-ntrk-gene-fusion.html
Newly approved Vitrakvi (larotrectinib) scored high patient response rates by inhibiting a rare chromosomal abnormality that drives tumor growth.
targeted therapylarotrectinibcouldmaketumors